Anti-vascular endothelial growth factor (VEGF) therapy can be used to treat most macular edemas (MEs) [6–10], and this has led to substantial improvements in the clinical management of decreased visual acuity (VA) [11–13]. The gene discussed is VEGFA; the disease is Meckel syndrome, type 1.